The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Antisense Oligonucleotide Therapeutics Market by Target Indication (Duchenne Muscular Atrophy, Spinal Muscular Atrophy, Familial Chylomicronemia Syndrome and others), Type of Therapy (Monotherapy and Combination), Type of Molecule (DNA Molecule and RNA Molecule) Type of Generation (First, Second and Third) and Key Geographies (North America, Europe, Asia- Pacific and Rest of the World): Industry Trends and Global Forecasts, 2020-2030

  • Lowest Price Guaranteed From USD 5,499

  • Published
    January 2021

  • Pages
    252

  • View Count
    2337

Example Insights

Antisense-Oligonucleotide-Therapeutics-Market-Context Antisense-Oligonucleotide-Therapeutics-Market-Developer Antisense-Oligonucleotide-Therapeutics-Market-Different-stages
Antisense-Oligonucleotide-Therapeutics-Market-Geographical-Distribution Antisense-Oligonucleotide-Therapeutics-Market-Grant-Analysis Antisense-Oligonucleotide-Therapeutics-Market-Partnerships-and-Collaborations
Antisense-Oligonucleotide-Therapeutics-Market-Future-opportunity Antisense-Oligonucleotide-Therapeutics-Market-Opportunity  

 

Overview

Since the approval of Vitravene™ (for the treatment of cytomegalovirus retinitis) in 1998, antisense oligonucleotide (ASO) therapies have evolved into a prominent class of therapeutics. In addition to the seven drugs, based on such molecules, that are commercially available, around 160 candidates are under development. Examples of recently approved antisense therapeutics include (in reverse chronological order) Viltepso™ (duchenne muscular dystrophy, March 2020), Vyondys 53® (duchenne muscular dystrophy, December 2019) and Waylivra® (hereditary transthyretin-mediated (hATTR) amyloidosis, May 2019). Given their ability to target the root cause of diseases, at the protein expression level, these disease-modifying interventions have potential applications across a wide range of therapeutic areas (including but not limited to oncological disorders, neurodegenerative disorders, respiratory disorders, and even certain rare genetic disorders). Further, recent advances in antisense oligonucleotide chemistry have enabled the development and synthesis of specialized oligonucleotides, having improved safety profiles and better cell targeting capabilities. In fact, these advanced variants of antisense oligonucleotide-based therapeutic candidates are deemed to possess the potential to cater to the unmet need for effective treatment options for diseases that were previously considered difficult to treat.

Presently, several drug developers, along with ASO technology providers, are actively engaged in the development of various antisense therapy candidates. Innovation in this field of research is mostly focused on improving cell targeting ability, target affinity, nuclease resistance, and optimizing toxicity profiles of antisense oligonucleotide candidates. Several big pharma players have also demonstrated interest in antisense oligonucleotide therapeutics and are investing both time and capital in this domain. The market has witnessed substantial partnership activity over the last few years. The activity in this segment of the industry has also attracted the attention of both private and public sector investors / investment funds, which have extended financial support to the initiatives of capable developer companies. Driven by encouraging clinical trial results, the antisense oligonucleotide therapies market is poised to witness healthy growth as multiple late stage drug candidates are approved and marketed over the coming decade.

Scope of the Report

The “Antisense Oligonucleotide Market, 2020-2030” report features an extensive study on the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next ten years. The study underlines an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape of antisense oligonucleotide therapeutics, providing information on type of antisense molecule (RNA molecule and DNA molecule), ASO generation (first-generation, second-generation, third-generation and next-generation), phase of development (commercial, clinical, preclinical, and discovery stage) of lead candidates, target genes, target disease indications, target therapeutic areas, route of administration (subcutaneous, intravenous, intrathecal, intravitreal and others) and type of therapy (monotherapy, combination therapy and both). In addition, it provides details on drug developer(s), including year of establishment, company size, and location of headquarters.
  • Tabulated profiles of prominent antisense oligonucleotide therapeutic developers. Each profile features a brief overview of the company, its financial information (if available), product portfolio, recent developments and an informed future outlook.
  • An in-depth analysis of completed, ongoing and planned clinical studies of various antisense oligonucleotide therapeutics, based on the various relevant parameters, such as trial registration year, trial phase, trial recruitment status, enrolled patient population, study design, leading industry sponsors / collaborators (in terms of number of trials conducted), trial focus, target therapeutic area and target genes, highlighting popular indications, popular interventions and regional distribution of trials.
  • A detailed analysis of grants that have been awarded to research institutes for antisense oligonucleotide therapeutic projects, in the period between 2017 and 2020 (till September), on the basis of important parameters, such as year of grant award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code, study section involved, type of recipient organizations and focus area. In addition, it highlights geographical distribution of recipient organizations, popular therapeutic areas, popular funding institute centers, prominent program officers, and popular recipient organizations.  
  • An analysis of the partnerships that have been established in the recent past (2016-2020), covering acquisitions and mergers, licensing agreements, product development agreements, research agreements, joint venture agreements and other relevant types of deals.
  • A case study on the oligonucleotide contract manufacturers and purification service providers, providing information on the year of establishment, company size, scale of operation, location of headquarters and type of purification method used.

One of the key objectives of the report was to estimate the existing market size and the future opportunity for antisense oligonucleotide therapeutics, over the next ten years. Based on multiple parameters, such as target patient population, likely adoption rate and the annual treatment cost, we have provided informed estimates on the evolution of antisense oligonucleotide therapeutics market for the period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] type of antisense molecule (RNA and DNA molecule) [B] different target indications (duchenne muscular dystrophy, spinal muscular atrophy, hereditary transthyretin-mediated (hATTR) amyloidosis, familial chylomicronemia syndrome, familial partial lipodystrophy, pouchitis, leber's congenital amaurosis, huntington’s disease and amyotrophic lateral sclerosis) [C] ASO generations (first-generation, second-generation and third-generation) [D] route of administration (intrathecal, intravenous, intravitreal, subcutaneous, and topical) [E] type of therapy (combination therapy and monotherapy) and [F] key geographical regions (US, UK, EU4, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  

All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading industry and non-industry players in this market?
  • What are the key therapeutic areas for which antisense oligonucleotide therapeutics are being / have been developed?
  • What are the prevalent trends within competitive landscape of antisense oligonucleotide therapeutics?
  • Which geographies are the most active in conducting clinical trials on antisense oligonucleotide therapeutics?
  • What kind of partnership models are commonly adopted by industry stakeholders? 
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It presents a high-level view on the current scenario within the antisense oligonucleotide therapeutics market and its evolution in the short-mid-term and long term.

Chapter 3 presents a general introduction to oligonucleotides, laying emphasis on the antisense oligonucleotide therapeutics, including information on their mechanism of action and types.  Additionally, the chapter features a brief discussion on the likely future trends in this field.

Chapter 4 provides information on more than 150 programs for antisense oligonucleotide therapeutics that are either approved or being developed across type of antisense molecule (RNA molecule and DNA molecule), ASO generation (first-generation, second-generation, third-generation and next-generation), phase of development (commercial, clinical, preclinical, and discovery stage) of lead candidates, target genes, target disease indications, target therapeutic areas, route of administration (subcutaneous, intravenous, intrathecal, intravitreal and others) and type of therapy (monotherapy, combination therapy and both). Additionally, the chapter includes information on drug developer(s), highlighting year of establishment, company size, and location of headquarters.

Chapter 5 provides tabulated profiles of the companies that are engaged in the development of at least two or more antisense oligonucleotide based therapies (in phase II and above). Each profile features a brief overview of the company, its financial information (if available), product portfolio, recent developments and an informed future outlook.

Chapter 6 provides a detailed analysis of completed, ongoing and planned clinical studies of various antisense oligonucleotide therapeutics, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry sponsors / collaborators (in terms of number of trials conducted), trial focus, target therapeutic area, target genes, popular indications, popular products and regional distribution of trials.

Chapter 7 provides an analysis of more than 380 grants that were awarded to research institutes engaged in antisense oligonucleotide therapeutics, in the period between 2017 and 2019 (till September) based on the important parameters, such year of grant award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code, focus area, study section involved, and type of recipient organizations. In addition, it highlights popular target therapeutic areas, popular funding institute centers, prominent program officers, and popular recipient organizations.  

Chapter 8 features a discussion of the various collaborations and partnerships that have been inked amongst stakeholders in this domain, since 2016. It includes a brief description of various types of partnership models (namely acquisitions and mergers, licensing agreements, product development agreements, research agreements, joint venture agreements and other agreements) that have been adopted by stakeholders in this domain. In addition, it includes a detailed analysis of partnerships, based on year of partnership, type of partnership, and regional activity.

Chapter 9 features a detailed market forecast analysis, highlighting the likely growth of antisense oligonucleotide therapeutics till the year 2030. The chapter presents a detailed market segmentation on the basis of  type of antisense molecule (RNA and DNA molecule), different target indications (duchenne muscular dystrophy, spinal muscular atrophy, hereditary transthyretin-mediated (hATTR) amyloidosis, familial chylomicronemia syndrome, familial partial lipodystrophy, pouchitis, leber's congenital amaurosis, huntington’s disease and amyotrophic lateral sclerosis), ASO generations (first-generation, second-generation and third-generation), route of administration (intrathecal, intravenous, intravitreal, subcutaneous, and topical), type of therapy (combination therapy and monotherapy) and key geographical regions (US, UK, EU4, Asia-Pacific and rest of the world) In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

Chapter 10 provides insights on current market landscape of oligonucleotide manufacturers focused on research and diagnostic, and therapeutic applications including information on the year of establishment, company size, scale of operation (small, medium, and large), location of headquarters and type of purification methods used.

Chapter 11 is a summary of the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights the evolutionary trends that were identified during the course of the study and are expected to influence the future of the antisense oligonucleotide therapeutics market.

Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 13 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION 
3.1. Chapter Overview
3.2. Overview on Oligonucleotides and Affiliated Medical Products
3.2.1. Types of Oligonucleotides
3.2.1.1. Antisense Oligonucleotides (ASOs)
3.2.1.2. Aptamers
3.2.1.3. miRNA
3.2.1.4. shRNA
3.2.1.5. siRNA
3.2.1.6. Other Oligonucleotides

3.3. Oligonucleotide Therapeutics
3.3.1. RNA-Interference Therapeutics
3.3.1.1. Components of RNA-Interference Therapeutics
3.3.1.2. Mechanism of RNA-Interference Therapeutics

3.3.2. Antisense Oligonucleotide Therapeutics
3.3.2.1. Mechanism of Antisense Oligonucleotide Therapeutics
3.3.3.2. Types of Antisense Oligonucleotide Therapeutics

3.4. Future Perspectives

4. ANTISENSE OLIGONUCLEOTIDE THERAPEUTICS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Antisense Oligonucleotide Therapeutics: Pipeline Review
4.2.1. Analysis by Type of Antisense Molecule 
4.2.2. Analysis by ASO Generation
4.2.3. Analysis by Phase of Development
4.2.4. Analysis by Target Genes
4.2.5. Analysis by Target Indications
4.2.6. Analysis by Therapeutic Areas
4.2.7. Analysis by Route of Administration
4.2.8. Analysis by Type of Therapy

4.3. Antisense Oligonucleotide Therapeutics: List of Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4. 3.3. Analysis by Location of Headquarters
4.4. Grid Analysis: Distribution by Phase of Development, Company Size and Location of Headquarters

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Antisense Therapeutics
5.2.1. Company Overview
5.2.2. Antisense Oligonucleotide Therapeutics Portfolio
5.2.3. Recent Developments and Future Outlook

5.3. Biogen
5.3.1. Company Overview
5.3.2. Financial Information 
5.3.3. Antisense Oligonucleotide Therapeutics Portfolio
5.3.4. Recent Developments and Future Outlook

5.4. Bio-Path Holdings
5.4.1. Company Overview
5.4.2. Antisense Oligonucleotide Therapeutics Portfolio
5.4.3. Recent Developments and Future Outlook

5.5. Ionis Pharmaceuticals
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Antisense Oligonucleotide Therapeutics Portfolio
5.5.4. Recent Developments and Future Outlook

5.6. ProQR Therapeutics
5.6.1. Company Overview
5.6.2. Antisense Oligonucleotide Therapeutics Portfolio
5.6.3. Recent Developments and Future Outlook

5.7. Sarepta Therapeutics
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Antisense Oligonucleotide Therapeutics Portfolio
5.7.4. Recent Developments and Future Outlook

5.8. Sterna Biologicals
5.8.1. Company Overview
5.8.2. Antisense Oligonucleotide Therapeutics Portfolio
5.8.3. Recent Developments and Future Outlook

5.9. Wave Life Sciences
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Antisense Oligonucleotide Therapeutics Portfolio
5.9.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Antisense Oligonucleotide Therapeutics: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Phase
6.3.3. Analysis by Trial Recruitment Status
6.3.4. Analysis by Trial Registration Year and Number of Patients Enrolled
6.3.5. Analysis by Study Design
6.3.6. Analysis by Type of Sponsor / Collaborator
6.3.7. Leading Players: Analysis by Number of Registered Trials
6.3.8. Word Cloud: Key Focus Areas
6.3.9. Analysis by Target Therapeutic Area
6.3.10. Analysis by Trial Registration Year and Target Gene
6.3.11. Popular Indications: Analysis by Number of Registered Trials
6.3.12. Popular Interventions: Analysis by Number of Registered Trials
6.3.13. Geographical Analysis by Number of Registered Trials
6.3.14. Geographical Analysis by Number of Patients Enrolled

7. ACADEMIC GRANTS ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Antisense Oligonucleotide Therapeutics: Analysis of Academic Grants
7.3.1. Analysis by Year of Grant Award
7.3.2. Analysis by Amount Awarded
7.3.3. Analysis by Administering Institute Center
7.3.4. Analysis by Support Period
7.3.5. Analysis by Administering Institute Center and Support Period
7.3.6. Analysis by Type of Grant Application
7.3.7. Analysis by Purpose of Grant Award
7.3.8. Analysis by Activity Code
7.3.9. Analysis by Study Section Involved
7.3.10. Analysis by Type of Recipient Organization
7.3.11. Word Cloud Analysis: Emerging Focus Areas
7.3.12. Geographical Distribution of Recipient Organizations

7.3.13. Popular Therapeutic Areas: Analysis by Number of Grants
7.3.14. Popular NIH Departments: Analysis by Number of Grants
7.3.15. Prominent Program Officers: Analysis by Number of Grants
7.3.16. Popular Recipient Organizations: Analysis by Number of Grants

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Antisense Oligonucleotide Therapeutics: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Partnership and Generation of Antisense Molecule Involved
8.3.4. Analysis by Type of Partnership and Target Therapeutic Area
8.3.5. Analysis by Year of Partnership and Type of Partner
8.3.6. Analysis by Type of Partnership and Type of Partner
8.3.7. Most Active Players: Analysis by Number of Partnerships
8.3.8. Regional Analysis
8.3.8.1. Intercontinental and Intracontinental Agreements

9. MARKET FORECAST AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Forecast Methodology and Key Assumptions
9.3. Global Antisense Oligonucleotide Therapeutics Market, 2020-2030
9.4. Global Antisense Oligonucleotide Therapeutics Market, 2020-2030: Individual Product Sales Forecasts
9.4.1. Alicaforsen (Atlantic Healthcare)
9.4.1.1. Target Patient Population
9.4.1.2. Sales Forecast

9.4.2. Eteplirsen (Sarepta Therapeutics)
9.4.2.1. Target Patient Population
9.4.2.2. Sales Forecast

9.4.3. Golodirsen (Sarepta Therapeutics)
9.4.3.1. Target Patient Population
9.4.3.2. Sales Forecast

9.4.4. Inotersen (Ionis Pharmaceuticals)
9.4.4.1. Target Patient Population
9.4.4.2. Sales Forecast

9.4.5. Sepofarsen (ProQR Therapeutics)
9.4.5.1. Target Patient Population
9.4.5.2. Sales Forecast

9.4.6. Tofersen (Biogen)
9.4.6.1. Target Patient Population
9.4.6.2. Sales Forecast

9.4.7. Tominersen (Roche)
9.4.7.1. Target Patient Population
9.4.7.2. Sales Forecast

9.4.8. Viltolarsen (Nippon Shinyaku)
9.4.8.1. Target Patient Population
9.4.8.2. Sales Forecast

9.4.9. Volanesorsen (Ionis Pharmaceuticals)
9.4.9.1. Target Patient Population
9.4.9.2. Sales Forecast

9.5. Global Antisense Oligonucleotide Therapeutics Market, 2020-2030: Distribution by Type of Antisense Molecule
9.5.1. Global Antisense Oligonucleotide Therapeutics Market for RNA Molecules, 2020-2030
9.5.2. Global Antisense Oligonucleotide Therapeutics Market for DNA Molecules, 2020-2030

9.6. Global Antisense Oligonucleotide Therapeutics Market, 2020-2030: Distribution by ASO Generation
9.6.1. Global Antisense Oligonucleotide Therapeutics Market for First-generation Products, 2021-2030
9.6.2. Global Antisense Oligonucleotide Therapeutics Market for Second-generation Products, 2020-2030
9.6.3. Global Antisense Oligonucleotide Therapeutics Market for Third-generation Products, 2020-2030

9.7. Global Antisense Oligonucleotide Therapeutics Market, 2020-2030: Distribution by Target Disease Indication
9.7.1. Global Antisense Oligonucleotide Therapeutics Market for Amyotrophic Lateral Sclerosis, 2023-2030
9.7.2. Global Antisense Oligonucleotide Therapeutics Market for Duchenne Muscular Dystrophy, 2020-2030
9.7.3. Global Antisense Oligonucleotide Therapeutics Market for Familial Chylomicronemia Syndrome, 2020-2030
9.7.4. Global Antisense Oligonucleotide Therapeutics Market for Familial Partial Lipodystrophy, 2024-2030
9.7.5. Global Antisense Oligonucleotide Therapeutics Market for Hereditary Transthyretin-Mediated (hATTR) Amyloidosis, 2020-2030
9.7.6. Global Antisense Oligonucleotide Therapeutics Market for Huntington’s Disease, 2024-2030
9.7.7. Global Antisense Oligonucleotide Therapeutics Market for Leber's Congenital Amaurosis, 2023-2030
9.7.8. Global Antisense Oligonucleotide Therapeutics Market for Pouchitis, 2021-2030
9.7.9. Global Antisense Oligonucleotide Therapeutics Market for Spinal Muscular Atrophy, 2020-2030

9.8. Global Antisense Oligonucleotide Therapeutics Market, 2020-2030: Distribution by Route of Administration
9.8.1. Global Antisense Oligonucleotide Therapeutics Market for Intrathecal Therapies, 2020-2030
9.8.2. Global Antisense Oligonucleotide Therapeutics Market for Intravenous Therapies, 2020-2030
9.8.3. Global Antisense Oligonucleotide Therapeutics Market for Intravitreal Therapies, 2023-2030
9.8.4. Global Antisense Oligonucleotide Therapeutics Market for Subcutaneous Therapies, 2020-2030
9.8.5. Global Antisense Oligonucleotide Therapeutics Market for Intraorifice Therapies, 2021-2030

9.9. Global Antisense Oligonucleotide Therapeutics Market, 2020-2030: Distribution by Type of Therapy
9.9.1. Global Antisense Oligonucleotide Therapeutics Market for Combination Therapies 2020-2030
9.9.2. Global Antisense Oligonucleotide Therapeutics Market for Monotherapies, 2020-2030

9.10. Global Antisense Oligonucleotide Market, 2020-2030: Geographical Distribution
9.10.1. Antisense Oligonucleotide Market in the US, 2020-2030
9.10.2. Antisense Oligonucleotide Market in Canada, 2020-2030
9.10.3. Antisense Oligonucleotide Market in the UK, 2020-2030
9.10.4. Antisense Oligonucleotide Market in Germany, 2020-2030
9.10.5. Antisense Oligonucleotide Market in France, 2020-2030
9.10.6. Antisense Oligonucleotide Market in Italy, 2020-2030
9.10.7. Antisense Oligonucleotide Market in Spain, 2020-2030
9.10.8. Antisense Oligonucleotide Market in Australia, 2025-2030
9.10.9. Antisense Oligonucleotide Market in Japan, 2020-2030
9.10.10. Antisense Oligonucleotide Market in Korea, 2020-2030
9.10.11. Antisense Oligonucleotide Market in Brazil, 2023-2030
9.10.12. Antisense Oligonucleotide Market in Israel, 2023-2030

10. CASE STUDY: OLIGONUCLEOTIDE MANUFACTURERS AND PURIFICATION SERVICES
10.1. Chapter Overview
10.2. List of Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications
10.2.1. Analysis by Year of Establishment
10.2.2. Analysis by Company Size
10.2.3. Analysis by Scale of Operation
10.2.4. Analysis by Location of Headquarters
10.2.5. Analysis by Type of Purification Method Used

10.3. List of Oligonucleotide Manufacturers Focused on Therapeutic Applications
10.3.1. Analysis by Year of Establishment
10.3.2. Analysis by Company Size
10.3.3. Analysis by Scale of Operation
10.3.4. Analysis by Location of Headquarters
10.3.5. Analysis by Type of Purification Method Used

11. CONCLUDING REMARKS

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Classification of Oligonucleotides
Figure 3.2 Key Components of RNA interference
Figure 3.3 Mechanism of RNA interference
Figure 3.4 Key Features of Antisense Oligonucleotides
Figure 3.5 Mechanism of Antisense Oligonucleotides
Figure 4.1 Antisense Oligonucleotide Therapeutics: Distribution by Type of Antisense Molecule
Figure 4.2 Antisense Oligonucleotide Therapeutics: Distribution by ASO Generation
Figure 4.3 Antisense Oligonucleotide Therapeutics: Distribution by Phase of Development
Figure 4.4 Antisense Oligonucleotide Therapeutics: Distribution by Target Genes
Figure 4.5 Antisense Oligonucleotide Therapeutics: Distribution by Target Indications
Figure 4.6 Antisense Oligonucleotide Therapeutics: Distribution by Therapeutic Areas
Figure 4.7 Antisense Oligonucleotide Therapeutics: Distribution by Route of Administration
Figure 4.8 Antisense Oligonucleotide Therapeutics: Distribution by Type of Therapy
Figure 4.9 Antisense Oligonucleotide Therapeutic Developers: Distribution by Year of Establishment
Figure 4.10 Antisense Oligonucleotide Therapeutic Developers: Distribution by Company Size
Figure 4.11 Antisense Oligonucleotide Therapeutic Developers: Distribution by Location of Headquarters
Figure 4.12 Grid Analysis: Distribution by Phase of Development of Therapeutics, Company Size and Location of Headquarters
Figure 5.1 Biogen: Annual Revenues, 2015-Q3 2020 (USD Million)
Figure 5.2 Ionis Pharmaceuticals: Annual Revenues, 2015-H1 2020 (USD Million)
Figure 5.3 Sarepta Therapeutics: Annual Revenues, 2015-H1 2020 (USD Million)
Figure 5.4 Wave Life Sciences: Annual Revenues, 2015-H1 2020 (USD Million)
Figure 6.1 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year
Figure 6.2 Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.3 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 6.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled
Figure 6.5 Clinical Trial Analysis: Distribution by Study Design
Figure 6.6 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 6.7 Leading Players: Distribution by Number of Registered Trials
Figure 6.8 Word Cloud: Key Focus Areas
Figure 6.9 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Figure 6.10 Clinical Trial Analysis: Distribution by Trial Registration Year and Target Gene
Figure 6.11 Popular Indications: Distribution by Number of Registered Trials
Figure 6.12 Popular Interventions: Distribution by Number of Registered Trials
Figure 6.13 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 6.14 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Figure 7.1 Grant Analysis: Cumulative Trend by Year of Grant Award, 2017-2020
Figure 7.2 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million), 2017-2020
Figure 7.3 Grant Analysis: Distribution by Administering Institute Center
Figure 7.4 Grant Analysis: Distribution by Support Period
Figure 7.5 Grant Analysis: Distribution by Administering Institute Center and Support Period
Figure 7.6 Grant Analysis: Distribution by Type of Grant Application
Figure 7.7 Grant Analysis: Distribution by Purpose of Grant Award
Figure 7.8 Grant Analysis: Distribution by Activity Code
Figure 7.9 Grant Analysis: Distribution by Study Section Involved
Figure 7.10 Grant Analysis: Distribution by Type of Recipient Organization
Figure 7.11 Word Cloud Analysis: Emerging Focus Areas
Figure 7.12 Grant Analysis: Geographical Distribution of Recipient Organizations
Figure 7.13 Popular Therapeutic Areas: Distribution by Number of Grants
Figure 7.14 Popular NIH Departments: Distribution by Number of Grants
Figure 7.15 Prominent Program Officers: Distribution by Number of Grants
Figure 7.16 Popular Recipient Organizations: Distribution by Number of Grants
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2020
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Type of Partnership and Generation of Antisense Molecule Involved
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership and Target Therapeutic Area
Figure 8.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 8.6 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 8.7 Most Active Players: Distribution by Number of Partnerships
Figure 8.8 Partnerships and Collaborations: Regional Distribution
Figure 8.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 Global Antisense Oligonucleotide Therapeutics Market, 2020-2030 (USD Million)
Figure 9.2 Alicaforsen: Sales Forecast, 2020-2030 (USD Million)
Figure 9.3 Eteplirsen: Sales Forecast, 2020-2030 (USD Million)
Figure 9.4 Golodirsen: Sales Forecast, 2020-2030 (USD Million)
Figure 9.5 Inotersen: Sales Forecast, 2020-2030 (USD Million)
Figure 9.6 Sepofarsen: Sales Forecast, 2020-2030 (USD Million)
Figure 9.7 Tofersen: Sales Forecast, 2020-2030 (USD Million)
Figure 9.8 Tominersen: Sales Forecast, 2020-2030 (USD Million)
Figure 9.9 Viltolarsen: Sales Forecast, 2020-2030 (USD Million)
Figure 9.10 Volanesorsen: Sales Forecast, 2020-2030 (USD Million)
Figure 9.11 Global Antisense Oligonucleotide Therapeutics Market, 2020-2030: Distribution by Type of Antisense Molecule (USD Million)
Figure 9.12 Global Antisense Oligonucleotide Therapeutics Market for RNA Molecules, 2020-2030 (USD Million)
Figure 9.13 Global Antisense Oligonucleotide Therapeutics Market for DNA Molecules, 2020-2030 (USD Million)
Figure 9.14 Global Antisense Oligonucleotide Therapeutics Market, 2020-2030: Distribution by ASO Generation (USD Million)
Figure 9.15 Global Antisense Oligonucleotide Therapeutics Market for First-generation Products, 2021-2030 (USD Million)
Figure 9.16 Global Antisense Oligonucleotide Therapeutics Market for Second-generation Products, 2020-2030 (USD Million)
Figure 9.17 Global Antisense Oligonucleotide Therapeutics Market for Third-generation Products, 2020-2030 (USD Million)
Figure 9.18 Global Antisense Oligonucleotide Therapeutics Market, 2020-2030: Distribution by Target Disease Indication (USD Million)
Figure 9.19 Global Antisense Oligonucleotide Therapeutics Market for Amyotrophic Lateral Sclerosis, 2023-2030 (USD Million)
Figure 9.20 Global Antisense Oligonucleotide Therapeutics Market for Duchenne Muscular Dystrophy, 2020-2030 (USD Million)
Figure 9.21 Global Antisense Oligonucleotide Therapeutics Market for Familial Chylomicronemia Syndrome, 2020-2030 (USD Million)
Figure 9.22 Global Antisense Oligonucleotide Therapeutics Market for Familial Partial Lipodystrophy, 2024-2030 (USD Million)
Figure 9.23 Global Antisense Oligonucleotide Therapeutics Market for Hereditary Transthyretin-Mediated (hATTR) Amyloidosis, 2020-2030 (USD Million)
Figure 9.24 Global Antisense Oligonucleotide Therapeutics Market for Huntington’s Disease, 2024-2030 (USD Million)
Figure 9.25 Global Antisense Oligonucleotide Therapeutics Market for Leber's Congenital Amaurosis, 2023-2030 (USD Million)
Figure 9.26 Global Antisense Oligonucleotide Therapeutics Market for Pouchitis, 2021-2030 (USD Million)
Figure 9.27 Global Antisense Oligonucleotide Therapeutics Market for Spinal Muscular Atrophy, 2020-2030 (USD Million)
Figure 9.28 Global Antisense Oligonucleotide Therapeutics Market, 2020-2030: Distribution by Route of Administration (USD Million)
Figure 9.29 Global Antisense Oligonucleotide Therapeutics Market for Intrathecal Therapies, 2020-2030 (USD Million)
Figure 9.30 Global Antisense Oligonucleotide Therapeutics Market for Intravenous Therapies, 2020-2030 (USD Million)
Figure 9.31 Global Antisense Oligonucleotide Therapeutics Market for Intravitreal Therapies, 2023-2030 (USD Million)
Figure 9.32 Global Antisense Oligonucleotide Therapeutics Market for Subcutaneous Therapies, 2020-2030 (USD Million)
Figure 9.33 Global Antisense Oligonucleotide Therapeutics Market for Intraorifice Therapies, 2021-2030 (USD Million)
Figure 9.34 Global Antisense Oligonucleotide Therapeutics Market, 2020-2030: Distribution by Type of Therapy (USD Million)
Figure 9.35 Global Antisense Oligonucleotide Therapeutics Market for Combination Therapies 2020-2030 (USD Million)
Figure 9.36 Global Antisense Oligonucleotide Therapeutics Market for Monotherapies, 2020-2030 (USD Million)
Figure 9.37 Global Antisense Oligonucleotide Market, 2020-2030: Distribution by Geography (USD Million)
Figure 9.38 Antisense Oligonucleotide Market in the US, 2020-2030 (USD Million)
Figure 9.39 Antisense Oligonucleotide Market in Canada, 2020-2030 (USD Million)
Figure 9.40 Antisense Oligonucleotide Market in the UK, 2020-2030 (USD Million)
Figure 9.41 Antisense Oligonucleotide Market in Germany, 2020-2030 (USD Million)
Figure 9.42 Antisense Oligonucleotide Market in France, 2020-2030 (USD Million)
Figure 9.43 Antisense Oligonucleotide Market in Italy, 2020-2030 (USD Million)
Figure 9.44 Antisense Oligonucleotide Market in Spain, 2020-2030 (USD Million)
Figure 9.45 Antisense Oligonucleotide Market in Australia, 2025-2030 (USD Million)
Figure 9.46 Antisense Oligonucleotide Market in Japan, 2020-2030 (USD Million)
Figure 9.47 Antisense Oligonucleotide Market in Korea, 2020-2030 (USD Million)
Figure 9.48 Antisense Oligonucleotide Market in Brazil, 2023-2030 (USD Million)
Figure 9.49 Antisense Oligonucleotide Market in Israel, 2023-2030 (USD Million)
Figure 10.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment
Figure 10.2 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size
Figure 10.3 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Scale of Operation
Figure 10.4 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Headquarters
Figure 10.5 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Purification Method Used
Figure 10.6 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment
Figure 10.7 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size
Figure 10.8 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Scale of Operation
Figure 10.9 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Headquarters
Figure 10.10 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Purification Method Used

List Of Tables

Table 4.1 Antisense Oligonucleotide Therapeutics: List of Drugs
Table 4.2 Antisense Oligonucleotide Therapeutics: List of Developers
Table 5.1 Antisense Oligonucleotide Therapeutics: List of Companies Profiled
Table 5.2 Antisense Therapeutics: Company Snapshot
Table 5.3 Drug Profile: ATL1102
Table 5.4 Drug Profile: ATL1103
Table 5.5 Antisense Therapeutics: Recent Developments and Future Outlook
Table 5.6 Biogen: Company Snapshot
Table 5.7 Drug Profile: Tofersen
Table 5.8 Drug Profile: ION541
Table 5.9 Biogen: Recent Developments and Future Outlook
Table 5.10 Bio-Path Holdings: Company Snapshot
Table 5.11 Drug Profile: Prexigebersen
Table 5.12 Drug Profile: BP1002
Table 5.13 Drug Profile: BP1003
Table 5.14 Bio-Path Holdings: Recent Developments and Future Outlook
Table 5.15 Ionis Pharmaceuticals: Company Snapshot
Table 5.16 Drug Profile: Spinraza®
Table 5.17 Drug Profile: Tegsedi®
Table 5.18 Drug Profile: Waylivra®
Table 5.19 Drug Profile: AKCEA-APOCIII-LRx
Table 5.20 Drug Profile: IONIS-PKK-LRx
Table 5.21 Drug Profile: IONIS-PKK-Rx
Table 5.22 Drug Profile: IONIS-ENAC-2.5Rx
Table 5.23 Drug Profile: IONIS-FB-LRx
Table 5.24 Drug Profile: IONIS-AGT-LRx
Table 5.25 Drug Profile: AKCEA-TTR-LRx
Table 5.26 Drug Profile: IONIS-GHR-LRx
Table 5.27 Drug Profile: ION253
Table 5.28 Drug Profile: IONIS-TMPRSS6-LRx
Table 5.29 Drug Profile: ION736
Table 5.30 Drug Profile: IONIS-AR-2.5Rx
Table 5.31 Drug Profile: ION224
Table 5.32 Drug Profile: ISIS-FGFR4RX
Table 5.33 Drug Profile: ISIS-GCCRRx
Table 5.34 Drug Profile: IONIS-GCGRRx
Table 5.35 Drug Profile: IONIS-HBV-LRx
Table 5.36 Drug Profile: ION251
Table 5.37 Drug Profile: ION 449
Table 5.38 Drug Profile: BIIB078
Table 5.39 Drug Profile: BIIB094
Table 5.40 Drug Profile: BIIB101
Table 5.41 Drug Profile: ISIS-EIF4ERx
Table 5.42 Drug Profile: BIIB080
Table 5.43 Drug Profile: ION663
Table 5.44 Drug Profile: ION674
Table 5.45 Drug Profile: ION537
Table 5.46 Drug Profile: ION929
Table 5.47 Drug Profile: ION363
Table 5.48 Drug Profile: ION373
Table 5.49 Drug Profile: ION283
Table 5.50 Drug Profile: ION260
Table 5.51 Drug Profile: ION581
Table 5.52 Drug Profile: ION716
Table 5.53 Drug Profile: ION904
Table 5.54 Drug Profile: ION547
Table 5.55 Ionis Pharmaceuticals: Recent Developments and Future Outlook
Table 5.56 ProQR Therapeutics: Company Snapshot
Table 5.57 Drug Profile: Sepofarsen
Table 5.58 Drug Profile: QR-421a
Table 5.59 Drug Profile: QR-1123
Table 5.60 Drug Profile: QR-411
Table 5.61 Drug Profile: QR-504a
Table 5.62 Drug Profile: QRX-704
Table 5.63 Drug Profile: QR-1011
Table 5.64 Drug Profile: QRX-461
Table 5.65 Drug Profile: QRX-136
Table 5.66 Drug Profile: QRX-1204
Table 5.67 ProQR Therapeutics: Recent Developments and Future Outlook
Table 5.68 Sarepta Therapeutics: Company Snapshot
Table 5.69 Drug Profile: Exondys 51
Table 5.70 Drug Profile: Vyondys 53
Table 5.71 Drug Profile: Amondys 45
Table 5.72 Drug Profile: SRP-5051
Table 5.73 Drug Profile: Exon 52
Table 5.74 Drug Profile: Exon 43
Table 5.75 Drug Profile: Exon 44
Table 5.76 Drug Profile: Exon 50
Table 5.77 Drug Profile: Exon 55
Table 5.78 Drug Profile: SRP-5052
Table 5.79 Drug Profile: SRP-5053
Table 5.80 Drug Profile: SRP-5044
Table 5.81 Drug Profile: SRP-5045
Table 5.82 Drug Profile: SRP-5050
Table 5.83 Sarepta Therapeutics: Recent Developments and Future Outlook
Table 5.84 Sterna Biologicals: Company Snapshot
Table 5.85 Drug Profile: SB010
Table 5.86 Drug Profile: SB011
Table 5.87 Drug Profile: SB012
Table 5.88 Sterna Biologicals: Recent Developments and Future Outlook
Table 5.89 Wave Life Sciences: Company Snapshot
Table 5.90 Drug Profile: WVE-120102
Table 5.91 Drug Profile: Suvodirsen
Table 5.92 Drug Profile: WVE-004
Table 5.93 Drug Profile: WVE-003
Table 5.94 Drug Profile: WVE-N531
Table 5.95 Drug Profile: Undisclosed Drug 1
Table 5.96 Drug Profile: Undisclosed Drug 2
Table 5.97 Drug Profile: Undisclosed Drug 3
Table 5.98 Drug Profile: Undisclosed Drug 4
Table 5.99 Drug Profile: Undisclosed Drug 5
Table 5.100 Drug Profile: Undisclosed Drug 6
Table 5.101 Wave Life Sciences: Recent Developments and Future Outlook
Table 8.1 Antisense Oligonucleotide Therapeutics: List of Partnerships and Collaborations
Table 9.1 Antisense Oligonucleotide Therapeutics: Summary of the Competitive Insights
Table 10.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: List of Industry Players
Table 10.2 Oligonucleotide Manufacturers Focused on Therapeutic Applications: List of Industry Players
Table 12.1 Antisense Oligonucleotide Therapeutics: Distribution by Type of Antisense Molecule
Table 12.2 Antisense Oligonucleotide Therapeutics: Distribution by ASO Generation
Table 12.3 Antisense Oligonucleotide Therapeutics: Distribution by Phase of Development
Table 12.4 Antisense Oligonucleotide Therapeutics: Distribution by Target Genes
Table 12.5 Antisense Oligonucleotide Therapeutics: Distribution by Target Indications
Table 12.6 Antisense Oligonucleotide Therapeutics: Distribution by Therapeutic Areas
Table 12.7 Antisense Oligonucleotide Therapeutics: Distribution by Route of Administration
Table 12.8 Antisense Oligonucleotide Therapeutics: Distribution by Type of Therapy
Table 12.9 Antisense Oligonucleotide Therapeutic Developers: Distribution by Year of Establishment
Table 12.10 Antisense Oligonucleotide Therapeutic Developers: Distribution by Company Size
Table 12.11 Antisense Oligonucleotide Therapeutic Developers: Distribution by Location of Headquarters
Table 12.12 Biogen: Annual Revenues, 2015-Q3 2020 (USD Million)
Table 12.13 Ionis Pharmaceuticals: Annual Revenues, 2015-H1 2020 (USD Million)
Table 12.14 Sarepta Therapeutics: Annual Revenues, 2015-H1 2020 (USD Million)
Table 12.15 Wave Life Sciences: Annual Revenues, 2015-H1 2020 (USD Million)
Table 12.16 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year
Table 12.17 Clinical Trial Analysis: Distribution by Trial Phase
Table 12.18 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 12.19 Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled
Table 12.20 Clinical Trial Analysis: Distribution by Study Design
Table 12.21 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 12.22 Leading Players: Distribution by Number of Registered Trials
Table 12.23 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Table 12.24 Clinical Trial Analysis: Distribution by Trial Registration Year and Target Gene
Table 12.25 Popular Indications: Distribution by Number of Registered Trials
Table 12.26 Popular Interventions: Distribution by Number of Registered Trials
Table 12.27 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Table 12.28 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Table 12.29 Grant Analysis: Cumulative Trend by Year of Grant Award, 2017-2020
Table 12.30 Grant Analysis: Cumulative Distribution by Amount Awarded, 2017-2020 (USD Million)
Table 12.31 Grant Analysis: Distribution by Administering Institute Center
Table 12.32 Grant Analysis: Distribution by Support Period
Table 12.33 Grant Analysis: Distribution by Administering Institute Center and Support Period
Table 12.34 Grant Analysis: Distribution by Type of Grant Application
Table 12.35 Grant Analysis: Distribution by Purpose of Grant Award
Table 12.36 Grant Analysis: Distribution by Activity Code
Table 12.37 Grant Analysis: Distribution by Study Section Involved
Table 12.38 Grant Analysis: Distribution by Type of Recipient Organization
Table 12.39 Grant Analysis: Geographical Distribution of Recipient Organizations
Table 12.40 Popular Therapeutic Areas: Distribution by Number of Grants
Table 12.41 Popular NIH Departments: Distribution by Number of Grants
Table 12.42 Prominent Program Officers: Distribution by Number of Grants
Table 12.43 Popular Recipient Organizations: Distribution by Number of Grants
Table 12.44 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2020
Table 12.45 Partnerships and Collaborations: Distribution by Type of Partnership
Table 12.46 Partnerships and Collaborations: Distribution by Type of Partnership and Generation of Antisense Molecule Involved
Table 12.47 Partnerships and Collaborations: Distribution by Type of Partnership and Target Therapeutic Area
Table 12.48 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 12.49 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 12.50 Most Active Players: Distribution by Number of Partnerships
Table 12.51 Partnerships and Collaborations: Regional Distribution
Table 12.52 Global Antisense Oligonucleotide Therapeutics Market, 2020-2030 (USD Million)
Table 12.53 Alicaforsen: Sales Forecast, 2020-2030 (USD Million)
Table 12.54 Eteplirsen: Sales Forecast, 2020-2030 (USD Million)
Table 12.55 Golodirsen: Sales Forecast, 2020-2030 (USD Million)
Table 12.56 Inotersen: Sales Forecast, 2020-2030 (USD Million)
Table 12.57 Sepofarsen: Sales Forecast, 2020-2030 (USD Million)
Table 12.58 Tofersen: Sales Forecast, 2020-2030 (USD Million)
Table 12.59 Tominersen: Sales Forecast, 2020-2030 (USD Million)
Table 12.60 Viltolarsen: Sales Forecast, 2020-2030 (USD Million)
Table 12.61 Volanesorsen: Sales Forecast, 2020-2030 (USD Million)
Table 12.62 Global Antisense Oligonucleotide Therapeutics Market, 2020-2030: Distribution by Type of Antisense Molecule (USD Million)
Table 12.63 Global Antisense Oligonucleotide Therapeutics Market for RNA Molecules, 2020-2030 (USD Million)
Table 12.64 Global Antisense Oligonucleotide Therapeutics Market for DNA Molecules, 2020-2030 (USD Million)
Table 12.65 Global Antisense Oligonucleotide Therapeutics Market, 2020-2030: Distribution by ASO Generation (USD Million)
Table 12.66 Global Antisense Oligonucleotide Therapeutics Market for First-generation Products, 2021-2030 (USD Million)
Table 12.67 Global Antisense Oligonucleotide Therapeutics Market for Second-generation Products, 2020-2030 (USD Million)
Table 12.68 Global Antisense Oligonucleotide Therapeutics Market for Third-generation Products, 2020-2030 (USD Million)
Table 12.69 Global Antisense Oligonucleotide Therapeutics Market, 2020-2030: Distribution by Target Disease Indication (USD Million)
Table 12.70 Global Antisense Oligonucleotide Therapeutics Market for Amyotrophic Lateral Sclerosis, 2023-2030 (USD Million)
Table 12.71 Global Antisense Oligonucleotide Therapeutics Market for Duchenne Muscular Dystrophy, 2020-2030 (USD Million)
Table 12.72 Global Antisense Oligonucleotide Therapeutics Market for Familial Chylomicronemia Syndrome, 2020-2030 (USD Million)
Table 12.73 Global Antisense Oligonucleotide Therapeutics Market for Familial Partial Lipodystrophy, 2024-2030 (USD Million)
Table 12.74 Global Antisense Oligonucleotide Therapeutics Market for Hereditary Transthyretin-Mediated (hATTR) Amyloidosis, 2020-2030 (USD Million)
Table 12.75 Global Antisense Oligonucleotide Therapeutics Market for Huntington’s Disease, 2024-2030 (USD Million)
Table 12.76 Global Antisense Oligonucleotide Therapeutics Market for Leber's Congenital Amaurosis, 2023-2030 (USD Million)
Table 12.77 Global Antisense Oligonucleotide Therapeutics Market for Pouchitis, 2021-2030 (USD Million)
Table 12.78 Global Antisense Oligonucleotide Therapeutics Market for Spinal Muscular Atrophy, 2020-2030 (USD Million)
Table 12.79 Global Antisense Oligonucleotide Therapeutics Market, 2020-2030: Distribution by Route of Administration (USD Million)
Table 12.80 Global Antisense Oligonucleotide Therapeutics Market for Intrathecal Therapies, 2020-2030 (USD Million)
Table 12.81 Global Antisense Oligonucleotide Therapeutics Market for Intravenous Therapies, 2020-2030 (USD Million)
Table 12.82 Global Antisense Oligonucleotide Therapeutics Market for Intravitreal Therapies, 2023-2030 (USD Million)
Table 12.83 Global Antisense Oligonucleotide Therapeutics Market for Subcutaneous Therapies, 2020-2030 (USD Million)
Table 12.84 Global Antisense Oligonucleotide Therapeutics Market for Intraorifice Therapies, 2021-2030 (USD Million)
Table 12.85 Global Antisense Oligonucleotide Therapeutics Market, 2020-2030: Distribution by Type of Therapy (USD Million)
Table 12.86 Global Antisense Oligonucleotide Therapeutics Market for Combination Therapies 2020-2030 (USD Million)
Table 12.87 Global Antisense Oligonucleotide Therapeutics Market for Monotherapies, 2020-2030 (USD Million)
Table 12.88 Global Antisense Oligonucleotide Market, 2020-2030: Distribution by Geography (USD Million)
Table 12.89 Antisense Oligonucleotide Market in the US, 2020-2030 (USD Million)
Table 12.90 Antisense Oligonucleotide Market in Canada, 2020-2030 (USD Million)
Table 12.91 Antisense Oligonucleotide Market in the UK, 2020-2030 (USD Million)
Table 12.92 Antisense Oligonucleotide Market in Germany, 2020-2030 (USD Million)
Table 12.93 Antisense Oligonucleotide Market in France, 2020-2030 (USD Million)
Table 12.94 Antisense Oligonucleotide Market in Italy, 2020-2030 (USD Million)
Table 12.95 Antisense Oligonucleotide Market in Spain, 2020-2030 (USD Million)
Table 12.96 Antisense Oligonucleotide Market in Australia, 2025-2030 (USD Million)
Table 12.97 Antisense Oligonucleotide Market in Japan, 2020-2030 (USD Million)
Table 12.98 Antisense Oligonucleotide Market in Korea, 2020-2030 (USD Million)
Table 12.99 Antisense Oligonucleotide Market in Brazil, 2023-2030 (USD Million)
Table 12.100 Antisense Oligonucleotide Market in Israel, 2023-2030 (USD Million)
Table 12.101 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment
Table 12.102 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size
Table 12.103 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Scale of Operation
Table 12.104 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Headquarters
Table 12.105 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Purification Method Used
Table 12.106 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment
Table 12.107 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size
Table 12.108 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Scale of Operation
Table 12.109 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Headquarters
Table 12.110 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Purification Method Used

List Of Companies

  1. Abbott
  2. AcedrA BioPharmaceutical 
  3. ACGT
  4. Achieve Life Sciences
  5. Agilent Technologies
  6. Ajinomoto Bio-Pharma Services
  7. Akcea Therapeutics
  8. Alcyone Lifesciences
  9. A Biotechnology & Pharmaceuticals
  10. Allianz BioInnovation
  11. Alta Bioscience
  12. AM Chemicals
  13. AmpTec
  14. Amylon Therapeutics
  15. Antisense Therapeutics
  16. Applied Biological Materials
  17. Aro Biotherapeutics
  18. AstraZeneca
  19. ATDBio
  20. Atlantic Healthcare
  21. ATZ Labs
  22. Axolabs
  23. Bachem
  24. Bayer
  25. BianoScience
  26. Bio Basic
  27. Biogen
  28. Biolegio
  29. BioMarin Pharmaceutical
  30. Bioneer
  31. Bio-Path Holdings
  32. Biosearch Technologies
  33. BioServe Biotechnologies
  34. BioSpring
  35. Bio-Synthesis
  36. Boston Children’s Hospital
  37. BR Biochem Life Sciences
  38. Bridgen
  39. Catabasis Pharmaceuticals
  40. ChemGenes
  41. Codiak BioSciences
  42. Cold Spring Harbor Laboratory
  43. CordenPharma
  44. Creative Biogene
  45. CUSABIO TECHNOLOGY
  46. CyberGene
  47. Daiichi Sankyo
  48. Dalton Pharma Services
  49. Deep Genomics
  50. Denali Therapeutics
  51. Dharmacon
  52. Duke University
  53. Dynacure
  54. EB Research Partnership
  55. Eli Lilly and Company
  56. Elim Biopharmaceuticals
  57. Empirico
  58. Eton Bioscience
  59. Eurofins Genomics
  60. Evotec
  61. Evox Therapeutics
  62. F. Hoffmn-La-Roche
  63. Firebrand Therapeutics
  64. F-Star Therapeutics
  65. FUTUREsynthesis
  66. GCC Biotech
  67. Genbiotech
  68. Gene Signal
  69. Gene Universal
  70. GeneDesign
  71. Genei Laboratories
  72. GenePharma
  73. General Biosystems
  74. GENERI BIOTECH
  75. GeneTx Biotherapeutics
  76. GENEWIZ
  77. GenScript
  78. Genuity Science
  79. GlaxoSmithKline
  80. Golden Mountain Partners
  81. Hanugen Therapeutics
  82. IBA Lifesciences
  83. inqaba biotec™
  84. Integrated DNA Technologies
  85. Ionis Pharmaceuticals
  86. Isarna Therapeutics
  87. Janssen Biotech
  88. Johns Hopkins University
  89. Johnson Matthey
  90. Kaneka Eurogentec
  91. KareBay Biochem
  92. Lions Eye Institute
  93. Lipigon Pharmaceuticals
  94. Lonza
  95. Mateon Therapeutics
  96. Medical Need
  97. Medigene
  98. Microsynth
  99. Midland Certified Reagent 
  100. Moligo Technologies
  101. National Cancer Institute
  102. National Institute of Allergy and Infectious Diseases
  103. NeuBase Therapeutics
  104. Nippon Shinyaku
  105. Nitto Denko Avecia
  106. Novartis
  107. Novatia
  108. NZYTech
  109. Oligomer
  110. OncoGenex Pharmaceuticals
  111. Oncoltelic
  112. Oregon Health & Science University
  113. Parexel
  114. Pfizer
  115. Primetech
  116. Prometheus Research
  117. ProQR Therapeutics
  118. PTC Therapeutics
  119. PureTech Health
  120. PYC Therapeutics
  121. Quintara Biosciences
  122. ReadCoor
  123. Rena Therapeutics
  124. Rexahn Pharmaceuticals
  125. Rockland Immunochemicals
  126. RogCon Biosciences
  127. Ruibo Bio-Technology
  128. Sarepta Therapeutics
  129. Scandinavian Gene Synthesis
  130. Secarna Pharmaceuticals
  131. Severn Biotech
  132. Sigma Aldrich
  133. Spring Bank Pharmaceuticals
  134. SRI International
  135. ST Pharm
  136. STA Pharmaceuticals
  137. Stanford University
  138. Sterna Biologicals
  139. Stoke Therapeutics
  140. Sumitomo Chemical
  141. Sun Yat-sen University
  142. Sunomix Biosciences
  143. Suzhou Ribo Life Science
  144. Synbio Technologies
  145. Syngene International
  146. TAG Copenhagen
  147. Takeda Pharmaceutical
  148. The University of Texas MD Anderson Cancer Center
  149. The University of Texas Southwestern Medical Center
  150. Thermo Fisher Scientific
  151. Thomas Jefferson University
  152. TriLink Biotechnologies
  153. Ultragenyx Pharmaceutical
  154. United States Army Medical Research Institute of Infectious Diseases
  155. United States Department of Defense
  156. University of California
  157. University of Florida
  158. University of Massachusetts Medical School
  159. University of Rochester
  160. Vallentech
  161. Vivantis Technologies
  162. Wave Life Sciences
  163. Wings Therapeutics
  164. Xcelris
  165. Zaphyr Pharmaceuticals
  166. Zhejiang Haichang Biotechnology

PRICING DETAILS

USD 5,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com